

QIBA FDG-PET/CT Tech Ctte Update Call

4 May 2012 at 9 AM CT

Draft Call Summary

In attendance:

Richard Wahl, MD (co-chair)

Keith Allberg

Barbara Croft, MD

Howard Higley, PhD

John M. Hoffman, MD

Blaine Horvath, RT

Lawrence (Larry) MacDonald, PhD

Eric Perlman, MD

Ling Shao, PhD

Anne Smith, PhD

John Sunderland, PhD

Valerie Treyer, PhD

Wenli Wang, PhD

Scott Wollenweber, PhD

Jeffrey Yap, PhD

Brian Zimmerman, PhD

RSNA

Joe Koudelik

Julie Lisiacki

Profile revisions discussed (Dr. Perlman)

- Blood glucose level (BGL) measurements discussed
 - Imaging within appropriate amount of time after injection (preference 50 minutes) was discussed
 - This information must be captured in the compliance section
 - There is generally a three-hour time difference after which the test may no longer be effective
- Adequate hydration needs greater emphasis
 - Patients frequently are fasting too long for contrast CT
 - Request for committee to review the whole document by the next call, 5/11, at least up to section III
 - Suggestions for replacement text needed for all issues to be addressed
 - Would like to have a finalized document prior to the QIBA Annual Meeting
 - Dr. Perlman proposed that all non-controversial comments to-date, up to section III, be finalized
 - would like to target the discussion to NEW suggested revision or comment ONLY
- Dr. Wahl to provide reference regarding definition of threshold level regarding measurement with contrast use

DICOM headers

- The group would like to encourage vendors to make DICOM headers more specific to residual dose

Next steps:

- Dr. Wahl to provide reference regarding definition of threshold level regarding measurement with contrast use
- Dr. Kinahan to circulate latest Profile version for ctte feedback; feedback as track changes welcome
- Dr Frank to send example (chart) to Dr Kinahan for the Profile section related to Image Interpretation Detail
- Dr Yap to provide histogram of radiotracer (syringe/line) flush example
- Next call agenda items to include residual dose, CMS reimbursement and QIBA compliance details

Next call: to continue discussion of the Profile at 9 am (CT) **May 11th**